Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry.

Ashley SE, Meyer BA, Ellis JA, Martino DJ.

J Vis Exp. 2018 Jun 21;(136). doi: 10.3791/57601.

PMID:
29985321
2.

Genetic variation at the Th2 immune gene IL13 is associated with IgE-mediated paediatric food allergy.

Ashley SE, Tan HT, Peters R, Allen KJ, Vuillermin P, Dharmage SC, Tang MLK, Koplin J, Lowe A, Ponsonby AL, Molloy J, Matheson MC, Saffery R, Ellis JA, Martino D; HealthNuts team.

Clin Exp Allergy. 2017 Aug;47(8):1032-1037. doi: 10.1111/cea.12942. Epub 2017 May 21.

PMID:
28544327
3.

The skin barrier function gene SPINK5 is associated with challenge-proven IgE-mediated food allergy in infants.

Ashley SE, Tan HT, Vuillermin P, Dharmage SC, Tang MLK, Koplin J, Gurrin LC, Lowe A, Lodge C, Ponsonby AL, Molloy J, Martin P, Matheson MC, Saffery R, Allen KJ, Ellis JA, Martino D; HealthNuts team; Barwon Infant Study, the Melbourne Atopy Cohort study, the Peanut Allergen Threshold Study and the Probiotic and Peanut Oral ImmunoTherapy study.

Allergy. 2017 Sep;72(9):1356-1364. doi: 10.1111/all.13143. Epub 2017 Apr 4.

PMID:
28213955
4.

AMPK and the neuroendocrine regulation of appetite and energy expenditure.

Stark R, Ashley SE, Andrews ZB.

Mol Cell Endocrinol. 2013 Feb 25;366(2):215-23. doi: 10.1016/j.mce.2012.06.012. Epub 2012 Jul 9. Review.

PMID:
22789749
5.

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.

Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, Saffery C, Chua YJ, Chau I.

J Clin Oncol. 2010 Sep 1;28(25):3945-50. doi: 10.1200/JCO.2010.29.2847. Epub 2010 Aug 2.

PMID:
20679619
6.

Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection.

Morgan VA, Kyriazi S, Ashley SE, DeSouza NM.

Acta Radiol. 2007 Jul;48(6):695-703.

PMID:
17611881
7.

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G; IMPACT Trialists Group.

J Clin Oncol. 2005 Aug 1;23(22):5108-16. Epub 2005 Jul 5.

PMID:
15998903
8.

Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival.

Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ.

Ann Oncol. 2005 Feb;16(2):267-72.

PMID:
15668282
9.

Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.

Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M.

Cancer. 2000 Dec 1;89(11):2145-52.

PMID:
11147583
10.

Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK, Dowsett M.

Clin Cancer Res. 2000 Feb;6(2):616-21.

11.

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.

Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M.

J Clin Oncol. 1999 Oct;17(10):3058-63.

PMID:
10506600
12.

Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma.

Makris A, Powles TJ, Kakolyris S, Dowsett M, Ashley SE, Harris AL.

Cancer. 1999 May 1;85(9):1996-2000.

PMID:
10223241
13.

Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study.

Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M.

Breast Cancer Res Treat. 1999 Jan;53(1):51-9.

PMID:
10206072
14.

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.

Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, Nash AG, Ford HT.

Ann Oncol. 1998 Nov;9(11):1179-84.

PMID:
9862047
15.

Variation in endometrial thickening in women with amenorrhea on tamoxifen.

Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M.

Breast Cancer Res Treat. 1998 Mar;48(1):81-5.

PMID:
9541192
16.

Cytological evaluation of biological prognostic markers from primary breast carcinomas.

Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA, Ashley SE, Ormerod MG, Titley JC, Osborne CK.

Breast Cancer Res Treat. 1997 May;44(1):65-74.

PMID:
9164679
17.

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.

Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC.

Clin Cancer Res. 1997 Apr;3(4):593-600.

18.

Hypofractionated stereotactic radiotherapy in the management of recurrent glioma.

Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M.

Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8.

PMID:
9069312
20.

Kinetic analysis of the swimming behavior of the goldfish, Carassius auratus, exposed to nickel: hypoactivity induced by sublethal concentrations.

Ellgaard EG, Ashley SE, Langford AE, Harlin DC.

Bull Environ Contam Toxicol. 1995 Dec;55(6):929-36. No abstract available.

PMID:
8601075
21.

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, et al.

J Clin Oncol. 1995 Mar;13(3):547-52.

PMID:
7884414
22.

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.

Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE, Priest K.

Br J Cancer. 1995 Feb;71(2):366-70.

23.

Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen.

Fernando IN, Titley JC, Powles TJ, Dowsett M, Trott PA, Ashley SE, Ford HT, Ormerod MG.

Br J Cancer. 1994 Dec;70(6):1211-6.

24.

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial.

Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S.

Lancet. 1994 May 28;343(8909):1318-21.

PMID:
7910323
25.

The Royal Marsden Hospital pilot tamoxifen chemoprevention trial.

Powles TJ, Jones AL, Ashley SE, O'Brien ME, Tidy VA, Treleavan J, Cosgrove D, Nash AG, Sacks N, Baum M, et al.

Breast Cancer Res Treat. 1994;31(1):73-82.

PMID:
7981459
26.

A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome.

Montes A, Powles TJ, O'Brien ME, Ashley SE, Luckit J, Treleaven J.

Eur J Cancer. 1993;29A(13):1854-7.

PMID:
8260241
27.

Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.

Jones AL, Powles TJ, Treleaven JG, Burman JF, Nicolson MC, Chung HI, Ashley SE.

Br J Cancer. 1992 Oct;66(4):744-7.

28.

Intracranial ependymoma: long-term results of a policy of surgery and radiotherapy.

Vanuytsel LJ, Bessell EM, Ashley SE, Bloom HJ, Brada M.

Int J Radiat Oncol Biol Phys. 1992;23(2):313-9.

PMID:
1587752
29.

Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.

Talbot DC, Smith IE, Mansi JL, Judson I, Calvert AH, Ashley SE.

J Clin Oncol. 1991 Dec;9(12):2141-7.

PMID:
1960556
31.

Postoperative radiotherapy in the management of spinal cord ependymoma.

Whitaker SJ, Bessell EM, Ashley SE, Bloom HJ, Bell BA, Brada M.

J Neurosurg. 1991 May;74(5):720-8.

PMID:
2013772
32.

The treatment and long-term prognosis of children with intracranial tumors: a study of 610 cases, 1950-1981.

Bloom HJ, Glees J, Bell J, Ashley SE, Gorman C.

Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):723-45. Erratum in: Int J Radiat Oncol Biol Phys 1990 Sep;19(3):829.

PMID:
2323965
33.

Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.

Hardy JR, Powles TJ, Judson IR, Sinnett HD, Ashley SE, Coombes RC, Ellin CL.

Eur J Cancer. 1990;26(7):824-7.

PMID:
2145904
34.

Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme.

Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB, McKinna JA.

Eur J Cancer. 1990;26(6):680-4.

PMID:
2144154
35.

Chemoprevention of breast cancer.

Powles TJ, Hardy JR, Ashley SE, Cosgrove D, Davey JB, Dowsett M, McKinna A, Nash AG, Rundle SK, Sinnett HD, et al.

Breast Cancer Res Treat. 1989 Oct;14(1):23-31.

PMID:
2690969
36.

Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).

Judson IR, Calvert AH, Rutty CJ, Abel G, Gumbrell LA, Graham MA, Evans BD, Wilman DE, Ashley SE, Cairnduff F.

Cancer Res. 1989 Oct 1;49(19):5475-9.

37.

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.

Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, et al.

Br J Cancer. 1989 Jul;60(1):126-31.

38.

Carboplatin (JM8), etoposide (VP16) and thoracic irradiation for small cell lung cancer (S.C.L.C.): an evaluation of lung toxicity.

Glaholm J, Repetto L, Yarnold JR, Smith IE, Ashley SE, Magrini S, Cherryman G.

Radiother Oncol. 1988 May;12(1):31-7.

PMID:
2841723
39.

Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging.

Vincent MD, Ashley SE, Smith IE.

Eur J Cancer Clin Oncol. 1987 Nov;23(11):1589-99.

PMID:
2828070

Supplemental Content

Loading ...
Support Center